ResMed | vs Steris
Steris reported revenue of $5.9 billion in fiscal 2026, about the same as ResMed |'s $5.7 billion in fiscal 2026. ResMed |'s revenue grew 9.8% in its latest year, and Steris' grew 8.7%. ResMed | had an operating margin of 33.4%, against 18.6% at Steris. Free cash flow was $1.6 billion at ResMed | and $972 million at Steris. Their fiscal years end in different months (June 30 and March 31), so the periods don't line up exactly.
Side by side
| ResMed | | Steris | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2026, Mar 31, 2026 |
| Revenue | $5.7B | $5.9B |
| Revenue growth | 9.8% | 8.7% |
| Revenue growth a year, last 5 years | 12.1% | 13.8% |
| Gross margin | 61.1% | 44.2% |
| Operating margin | 33.4% | 18.6% |
| Net margin | 26.9% | 13.2% |
| Free cash flow | $1.6B | $972M |
| Free cash flow margin | 29.2% | 16.4% |
| Return on capital | 26.7% | 9.6% |
| Net debt to EBITDA | −0.4x | 0.9x |
| Dividends and buybacks | $1.0B | $477M |
| Change in diluted share count | −0.9% | −0.4% |
| Last close | $253.20 | $230.12 |
| P/E at the last close | 24.3× | 28.1× |
| Insider trades, last 12 months | sold $22.4 million | sold $9.8 million |
| Piotroski F-score | 6 of 9 | 9 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ResMed |Steris
Operating margin
Percent of revenue
ResMed |Steris
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ResMed |Steris